CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
· manilatimes.net
Varsetatug masetecan ('Varseta-M”) Program:
Varsetatug masetecan ("Varseta-M”) Program:
- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational stud...